All In Biotech

Drug Trial Radar · NCT06920771

A Randomized, Double-Blind, Placebo-Controlled, Multi-Centre Study to Assess the Efficacy of PURETHAL Mites Mixture 50,000 AUeq/mL Subcutaneous Immunotherapy in Adult Subjects With Moderate to Severe Allergic Rhinitis/Rhinoconjunctivitis With or Without Asthma Induced by House Dust Mite (HDM)

A Randomized, Double-Blind, Placebo-Controlled, Multi-Centre Study to Assess the Efficacy of PURETHAL Mites Mixture 50,000 AUeq/mL Subcutaneous Immunotherapy in Adult Subjects With Moderate to Severe Allergic Rhinitis/Rhinoconjunctivitis With or Without Asthma Induced by House Dust Mite

Last checked: Nov 20, 2026Latest source record: Aug 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 691 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

691

Actual

Start

Sep 9, 2024

Primary completion

Mar 30, 2026

Study completion Mar 30, 2026

Sponsor

Lead sponsor
HAL AllergyIndustry
Sponsor type
Industry
Collaborators
Ergomed; ClinCompetence Cologne GmbH
First posted
Apr 10, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Rationale: Allergic rhinitis/rhinoconjunctivitis (ARC) is a global health problem, affecting 10-25% of the population. Allergen-specific immunotherapy is the only disease-modifying therapeutic option for subjects with house dust mites (HDM)-induced allergic rhinitis/rhinoconjunctivitis. This Phase 3 clinical study aims to demonstrate the effecacy of PURETHAL Mites (PM) Mixture subcutaneous immunotherapy (SCIT) compared to a placebo over one year of treatment in patients with moderate to severe HDM- induced allergic rhinitis/rhinoconjunctivitis (ARC), while also prioritizing the safety of the treatment. PM Mixture is a suspension of chemically modified extract from the house dust mites Dermatophagoides pteronyssinus (D. pter) and Dermatophagoides farinae (D. far), adsorbed to aluminium hydroxide. Modified extracts (allergoids) are associated with reduced allergenicity but with preserved immunogenicity. Based on the previous studies the dose of 0.5 mL of PM Mixture solution with concentration 50,000 AUeq/mL (allergen units in millilitre) was selected for this Phase 3 clinical study. Objectives: The primary objective is to assess the efficacy of PM Mixture 50,000 AUeq/mL (0.5 mL) SCIT based on an average Total Combined Rhinitis Score (TCRS), which will be compared between PM Mixture and placebo groups. The TCRS consists of rhinitis symptom score and medication score measured daily over the last 8 weeks of the 1 year treatment. Other secondary efficacy parameters will be compared between treatment groups to show efficacy: rhinitis symptom and medication scores separately as well as a combined symptom and medication score for nasal symptoms only (CSMS(n)); Total Combined Conductivities Score; nasal provocation test; immunological blood markers such as immunoglobulins E, G and G4; and Rhinitis Quality of Life Questionnaire (standardised) (RQLQ(S)). Trial design: This is a randomized, double-blind, placebo controlled multi-centre clinical trial where subjects are participating for about 14 months. Trial population: Patients (18-65 years of age) suffering from moderate to severe ARC induced by HDM with or without controlled asthma can be included in the study. The main criteria to evaluate the HDM allergy will be done by the following parameters: allergic medical history to HDM minimum 1 year; positive skin prick test and nasal provocation test HDM D. pter and/or D. far; certain level of allergen-specific immunoglobulin E to D. pter or D. far, and most importantly they should have sufficient rhinitis symptom score measured during 2 weeks at screening. Additionally patients should have sufficient lung functions confirmed by the spirometry, they may have asthma which should be controlled. Patients with a chronic or acute disease that might place the subject at an additional risk will not be included. Certain medications which can interfere with the study treatment or increase the health risks should be washed-out and can not be taken during the study. Approximately 920 HDM-allergic subjects will be screened in order after the screening period to enroll 552 subjects.

Conditions

  • House Dust Mite Allergy
  • House Dust Mite Rhinitis

Interventions

  • PURETHAL Mites 50,000 AUeq/mlBiological

    Biological/Vaccine: Placebo Increasing volumes of placebo, will be administered by subcutaneous injection (starting with 0.05 ml) at weekly intervals till the maintenance dose (0.5 ml) is reached. Subsequently, maintenance dosages, corresponding to 0.5 ml of placebo, are given at 4-weekly intervals

  • Biological/Vaccine: PlaceboBiological

    Increasing dosages, corresponding to increasing volumes of drug solution (starting with 0.05 ml), will be administered by subcutaneous injection at weekly intervals till the maintenance dose (0.5 ml) is reached. Subsequently, maintenance dosages, corresponding to 0.5 ml of drug solution, are given at 4-weekly intervals.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Primary objectiveTime frame: Last 8 weeks (before end of study) of the intervention.

Locations

68 sites in 5 countries. Site status is shown where the registry gives one.

  • UMBAL Kaspela

    Plovdiv, Bulgaria

  • Medical Center Prolet EOOD

    Rousse, Bulgaria

  • Medical Center Smolyan

    Smolyan, Bulgaria

  • DCC Convex

    Sofia, Bulgaria

  • Diagnostic-Consulativ Senter Ascendent

    Sofia, Bulgaria

  • University Hospital Alexandrovska

    Sofia, Bulgaria

  • Emovis GmbH

    Berlin, Germany

  • Praxis Dr. Ginko

    Bonn, Germany

  • Praxis Dr. Elke Decot

    Dreieich, Germany

  • HNO-Praxis Dr. Udo Schäfer

    Dresden, Germany

  • HNO Praxis Dr. Uta Thieme

    Duisburg, Germany

  • Medizentrum Essen-Borbeck

    Essen, Germany

  • Pneumologisches Forschungsinstitut Hohegeest GbR

    Geesthacht, Germany

  • HNO-Facharztpraxis Alte Post

    Göttingen, Germany

  • HNO Research GmbH

    Itzehoe, Germany

  • Hospital Schleswig-Holstein. Klinik für Dermatologie, Venerologie und Allergologie.

    Kiel, Germany

  • BAG Prof. G. Hoheisel/Dr. A. Bonitz Praxis für Pneumologie und Allergologie - Studienzentrum

    Leipzig, Germany

  • Praxis Dr. Bohn

    Mittweida, Germany

  • Ballenberger, Freytag, Wenisch -Institut für klinische Forschung GmbH

    Neu-Isenburg, Germany

  • Studienzentrum MOL BAG Dres. E.Hippke & S. Runge

    Neuenhagen, Germany

  • KliFOs - Klinische Forschung Osnabrück

    Osnabrück, Germany

  • Studienzentrum Dr.Schlenska

    Peine, Germany

  • Studienzentrum Dr.Laßmann

    Saalfeld, Germany

  • Allergo GmbH - Prüfzentrum Schorndorf

    Schorndorf, Germany

  • Klinikum Stuttgart - Krankenhaus Bad Cannstatt

    Stuttgart, Germany

  • LOR Clinic

    Riga, Latvia

  • The Center of Investigation in Treatment of Allergyc Diseases

    Riga, Latvia

  • CD8 clinic

    Kaunas, Lithuania

  • Lithuanian University of Health Sciences Kauno klinikos

    Kaunas, Lithuania

  • Inovatyvios alergologijos centras

    Vilnius, Lithuania

  • JSC Center for Diagnosis and Treatment of Allergic Diseases

    Vilnius, Lithuania

  • JSC Family Doctor

    Vilnius, Lithuania

  • JSC Inlita

    Vilnius, Lithuania

  • JSC Verkiu clinic

    Vilnius, Lithuania

  • NZOZ Homeo Medicus Poradnia Alergologiczna

    Bialystok, Poland

  • Prywatna Praktyka Lekarska Gabinet Pediatryczno-Alergologiczny Anna Płoszczuk

    Bialystok, Poland

  • Specjalistyczna Praktyka Lekarska AlerMedica

    Bialystok, Poland

  • Centrum Medyczne KERmed

    Bydgoszcz, Poland

  • Pratia - Ośrodek Badań Klinicznych

    Częstochowa, Poland

  • Clinica Vitae Spółka z o. o.

    Gdansk, Poland

Showing 40 of 68 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.